Fig. 2From: A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerSubgroup analysis for PFS. Data are for phase II part; [1] overall results calculated as in the primary model analysis. ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survivalBack to article page